A highly sensitive and specific reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay to detect ZIKV nucleic acid in biological samples is described. The disclosed assay is capable of detecting as few as one RNA copy per μl and can be performed in a clinical or field setting with minimal equipment and technological expertise. Oligonucleotide primers and kits for detecting ZIKV nucleic acid are also described.

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.

A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.6, CasX, or argonaute protein, which target at least one nucleotide sequence of the JCV genome.

The invention relates to methods for determining the severity of a disease caused by a coronavirus infection, comprising quantifying the level of cellular RNA of RNase P in a blood sample of a subject.

The invention relates to methods for determining the severity of a disease caused by a coronavirus infection, comprising quantifying the level of cellular RNA of RNase P in a blood sample of a subject.

The present invention relates to a method of detecting specific nucleic acid sequences and a device for performing the method therein. The specific nucleic acid may be prepared from a subject-specimen or from an environmental specimen and the method is performed in isothermal conditions.

The present invention provides a target RNA detection method based on a dCas9/gRNA complex. A target RNA detection method according to the present invention can detect target RNA with the naked eye and without separate gene isolation and amplification steps, and, in particular, can rapidly and accurately detect target RNA through excellent target specificity and rapidity, and thus can exhibit excellent effects on the detection of various pathogens and/or viruses.

The present invention provides a target RNA detection method based on a dCas9/gRNA complex. A target RNA detection method according to the present invention can detect target RNA with the naked eye and without separate gene isolation and amplification steps, and, in particular, can rapidly and accurately detect target RNA through excellent target specificity and rapidity, and thus can exhibit excellent effects on the detection of various pathogens and/or viruses.

The first object of the invention is primer sets for amplifying the nucleotide sequence of the L2 gene of human papillomavirus type 16 or L1 gene of human papillomavirus type 18. The second object of the invention is a method for detecting HPV16 or HPV18 viruses. Another object of the invention is a method of detecting HPV16 and HPV18 infections. A fourth object of the invention is a kit for detecting HPV16 or HPV18 infections.

Provided herein are methods and compositions for providing identification and/or traceability of biological materials. In certain embodiments, methods are provided including steps of: determining a sequence of at least one unique identifier sequence in the genomic DNA of a biological entity; validating identification of the biological entity by verifying presence of the unique identifier sequence in the genomic DNA and comparing the sequence of the unique identifier sequence with a database to confirm uniqueness; providing an indication of acceptability to produce a biological material from the biological entity; and inputting the unique identifier sequence into a database entry of the database and associating the unique identifier sequence with identification and/or tracking information; thereby providing traceability by reading the unique identifier sequence and retrieving the corresponding database entry to obtain the identification and/or tracking information. Oligonucleotides, cassettes, and compositions for providing identification and/or traceability of biological materials are also provided.